购物车
- 全部删除
- 您的购物车当前为空
HSD17B13-IN-29 (Compound 53) 是一种抑制羟基类固醇 17β-脱氢酶 13 (HSD17B13) 的化合物,其雌二醇的IC50值为 ≤ 0.1 μM。该化合物主要用于研究肝病、代谢性疾病或心血管疾病,例如非酒精性脂肪肝病 (NAFLD)、非酒精性脂肪肝炎 (NASH),或药物性肝损伤 (DILI)。
HSD17B13-IN-29 (Compound 53) 是一种抑制羟基类固醇 17β-脱氢酶 13 (HSD17B13) 的化合物,其雌二醇的IC50值为 ≤ 0.1 μM。该化合物主要用于研究肝病、代谢性疾病或心血管疾病,例如非酒精性脂肪肝病 (NAFLD)、非酒精性脂肪肝炎 (NASH),或药物性肝损伤 (DILI)。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | Compound 53, also known as HSD17B13-IN-29, is an inhibitor targeting hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC 50 ≤ 0.1 μM for estradiol. This compound is applicable in the study of liver, metabolic, and cardiovascular diseases, including NAFLD and NASH, and for investigating drug-induced liver injury (DILI) [1]. |
分子量 | 465.29 |
分子式 | C23H14Cl2N4O3 |
CAS No. | 2770246-48-3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
评论内容